WO2021182829A1 - Souche de lactobacillus rhamnosus ayant une fonction immunomodulatrice intestinale et une activité préventive ou thérapeutique pour les maladies intestinales inflammatoires - Google Patents

Souche de lactobacillus rhamnosus ayant une fonction immunomodulatrice intestinale et une activité préventive ou thérapeutique pour les maladies intestinales inflammatoires Download PDF

Info

Publication number
WO2021182829A1
WO2021182829A1 PCT/KR2021/002857 KR2021002857W WO2021182829A1 WO 2021182829 A1 WO2021182829 A1 WO 2021182829A1 KR 2021002857 W KR2021002857 W KR 2021002857W WO 2021182829 A1 WO2021182829 A1 WO 2021182829A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
culture
lactobacillus
ldtm7511
inflammatory bowel
Prior art date
Application number
PCT/KR2021/002857
Other languages
English (en)
Korean (ko)
Inventor
허철성
박현준
여소영
최인석
김병국
주재량
Original Assignee
주식회사 종근당바이오
서울대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 종근당바이오, 서울대학교산학협력단 filed Critical 주식회사 종근당바이오
Publication of WO2021182829A1 publication Critical patent/WO2021182829A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention provides a novel Lactobacillus rhamnosus LDTM7511 strain (accession number KCTC 18735P), a culture thereof, a concentrate of the culture, a dried product of the culture, or a combination thereof as an active ingredient. It relates to a composition for prevention, improvement or treatment.
  • Inflammatory bowel disease is an idiopathic disease that causes chronic and recurrent inflammation of the digestive tract and damage to intestinal mucosal tissue.
  • CD Crohn's disease
  • UC ulcerative colitis
  • an increase in inflammatory cytokines due to an immune function abnormality in the intestinal wall or invasion of an environmental antigen in the intestine and dysbiosis of the intestinal flora due to pathogen infection are suggested as major causes.
  • the diversity of intestinal bacteria is reduced, the overgrowth and adhesion of Enteribacteriaceae among certain symbiotic bacteria, Proteobacteria, and specific pathogens such as invasive Escherichia coli (AIEC) and Mycobacterium (Mycobacterium). Infection is known to cause intestinal imbalance.
  • AIEC invasive Escherichia coli
  • Mycobacterium Mycobacterium
  • mesalamine In the treatment of inflammatory bowel disease, mesalamine (Mesalazine or 5-aminosalicylic acid), which is a type of anti-inflammatory agent focused on suppressing inflammation and improving symptoms, is mainly used as the first-line treatment. Antibiotics are administered if mesalamine does not respond, and steroids may be administered if the symptoms of Crohn's disease or ulcerative colitis are acutely exacerbated. However, 20-40% of patients are ineffective with these drugs, and the use of the drug is limited in children and adolescent patients, and there are divided opinions about the side effects and continuous efficacy of the drug.
  • probiotic lactic acid bacteria prevent the adhesion of pathogenic bacteria to the intestine and prevent the invasion of pathogenic bacteria by producing their own antibacterial substances such as lactic acid and bacteriocin.
  • the intestinal flora caused by dysbiosis by these pathogenic microorganisms, it can affect specific organs of the host, and can affect the interaction between the intestinal flora and the intestinal mucosa.
  • it is possible to improve the function of the intestinal mucosa by increasing the intestinal mucosa adhesion ability, the amount of mucus secretion, the production of protective substances such as mucin, and the tight junction integrity of the intestinal mucosa.
  • probiotic microorganisms Although the potential effect of probiotic microorganisms is expected, the mechanism of action for probiotics is not yet clear, and additional research results are required. In particular, for diseases that are not clearly identified, such as inflammatory bowel disease, the development of a composition capable of solving various causes in an integrated manner is required.
  • the present inventors tried to develop a probiotic strain that can be applied as food and medicine for the prevention, improvement or treatment of inflammatory bowel disease in the future. As a result, by identifying the antibacterial and anti-inflammatory effects of the Lactobacillus rhamnosus LDTM7511 strain, the present invention was completed.
  • an object of the present invention is to provide a Lactobacillus rhamnosus LDTM7511 strain of accession number KCTC 18735P.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory bowel disease comprising the Lactobacillus rhamnosus LDTM7511 strain as an active ingredient.
  • Another object of the present invention is to provide a food composition for preventing or improving inflammatory bowel disease comprising the Lactobacillus rhamnosus LDTM7511 strain as an active ingredient.
  • Another object of the present invention is to provide a method for treating inflammatory bowel disease, comprising administering the Lactobacillus rhamnosus LDTM7511 strain to an individual in need thereof.
  • Another object of the present invention is to provide a treatment for inflammatory bowel disease of the Lactobacillus rhamnosus LDTM7511 strain.
  • the present inventors tried to develop a probiotic strain that can be applied as food and medicine for the prevention, improvement or treatment of inflammatory bowel disease in the future. As a result, the antibacterial and anti-inflammatory effects of the Lactobacillus rhamnosus LDTM7511 strain were investigated.
  • the present invention is Lactobacillus rhamnosus LDTM7511 strain of accession number accession number KCTC 18735P, a culture thereof, a concentrate of the culture, a dried product of the culture, or a combination thereof as an active ingredient Prevention of inflammatory bowel disease , to a composition for improvement or treatment.
  • One aspect of the present invention relates to a Lactobacillus rhamnosus LDTM7511 strain of accession number accession number KCTC 18735P.
  • the Lactobacillus rhamnosus LDTM7511 strain is characterized in that it comprises a 16s rRNA nucleotide sequence of SEQ ID NO: 1.
  • the nucleotide sequence of SEQ ID NO: 1 has 99% homology with Lactobacillus rhamnosus NBRC 3425, a test strain, and 1% difference between the two strains was recognized and it was found to be a novel strain.
  • the obtained novel strain was named Lactobacillus rhamnosus LDTM7511 strain, and was deposited with the Korea Research Institute of Bioscience and Biotechnology (KCTC) as of October 31, 2018, and was given an accession number KCTC 18735P.
  • Lactobacillus rhamnosus LDTM7511 strain can be obtained by isolation and identification from a fecal sample, and the cell properties of the strain are as follows:
  • the Lactobacillus rhamnosus LDTM7511 strain has antibacterial activity against the causative bacteria of inflammatory bowel disease.
  • IBD inflammatory bowel disease
  • the inflammatory bowel disease may be Crohn's disease (CD), ulcerative colitis (UC) and/or Behet's disease, but is not limited thereto.
  • CD Crohn's disease
  • UC ulcerative colitis
  • Behet's disease but is not limited thereto.
  • the causative agent of the inflammatory bowel disease may be Mycobacterium paratuberculosis, Helicobacter pylori, Campylobacter coli and / or Escherichia coli,
  • the present invention is not limited thereto.
  • the Lactobacillus rhamnosus LDTM7511 strain is a living probiotic, has resistance to the stress environment in the intestine, has no hemolytic activity, and is harmful caused by protein components of food in the intestine Does not produce biogenic amines.
  • antibiotic susceptibility meeting the criteria of EFSA was confirmed to ensure safety, and excellent anti-inflammatory effect was confirmed.
  • Another aspect of the present invention is any one selected from the group consisting of a Lactobacillus rhamnosus LDTM7511 strain of accession number KCTC 18735P, a culture of the strain, a concentrate of the culture, a dried product of the culture, and a combination thereof It relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, including the above.
  • the composition comprises a Lactobacillus paracasei LDTM7411 strain and/or a Lactobacillus sakei LDTM7601 strain, a culture of the strain, a concentrate of the culture, a dried product of the culture, and a combination thereof. It may further include any one or more selected from the group.
  • the Lactobacillus paracasei LDTM7411 strain is characterized in that it comprises a 16s rRNA nucleotide sequence of SEQ ID NO: 2.
  • the nucleotide sequence of SEQ ID NO: 2 has 99% homology with Lactobacillus paracasei FC7, a test strain, and 1% difference between the two strains was recognized and it was found to be a novel strain.
  • the new strain obtained above was named Lactobacillus paracasei LDTM7411 strain, and was deposited with the Korea Research Institute of Bioscience and Biotechnology (KCTC) as of October 31, 2018 and was given an accession number KCTC 18734P.
  • Lactobacillus paracasei LDTM7411 strain can be obtained by isolation and identification from a fecal sample, and the cell properties of the strain are as follows:
  • the Lactobacillus paracasei LDTM7411 strain has antibacterial activity against the causative bacteria of inflammatory bowel disease.
  • the Lactobacillus sakei LDTM7601 strain is characterized in that it contains the 16s rRNA nucleotide sequence of SEQ ID NO: 3.
  • the nucleotide sequence of SEQ ID NO: 3 has 99% homology with Lactobacillus sakei NBRC 15893, a test strain, and 1% difference between the two strains was recognized, which was confirmed as a novel strain.
  • the obtained novel strain was named Lactobacillus sakei LDTM7601 strain, and was deposited with the Korea Research Institute of Bioscience and Biotechnology (KCTC) on October 31, 2018, and was given an accession number KCTC 18736P.
  • Lactobacillus sakei LDTM7601 strain can be obtained by isolating and identifying the salted squid sample, and the cell properties of the strain are as follows:
  • the Lactobacillus sakei LDTM7601 strain has antibacterial activity against the causative bacteria of inflammatory bowel disease.
  • the Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains are living probiotics, have resistance to the stress environment in the intestine, have no hemolytic activity, and are caused by the protein component of food in the intestine. It does not generate harmful biologic amines that are generated.
  • antibiotic susceptibility meeting the criteria of EFSA was confirmed to ensure safety, and excellent anti-inflammatory effect was confirmed.
  • the Lactobacillus rhamnosus LDTM7511 strain, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains are mixed and used as a complex strain to effectively inhibit excessive inflammatory response, as well as However, it was confirmed that the effect of improving the intestinal microflora was excellent.
  • Another aspect of the present invention is any selected from the group consisting of Lactobacillus rhamnosus LDTM7511 strain of accession number KCTC 18735P, a culture of the strain, a concentrate of the culture, a dried product of the culture, and a combination thereof It relates to a food composition for preventing or improving inflammatory bowel disease comprising one or more as an active ingredient.
  • the composition comprises a Lactobacillus paracasei LDTM7411 strain and/or a Lactobacillus sakei LDTM7601 strain, a culture of the strain, a concentrate of the culture, a dried product of the culture, and a combination thereof. It may further include any one or more selected from the group.
  • compositions of the present invention is the active ingredient, the strain, its culture, the culture containing cells other than the isolated and/or purified cells of the strain, the extract of the cells, the culture supernatant, their concentrates, and concentrates , dried products, and, if necessary, diluents, dilutions, etc., and may include culture solutions and substances in all states obtained by treating the culture.
  • the culture method, extraction method, separation method, concentration method, drying method, dilution method, etc. of the strain are not particularly limited.
  • the medium for culturing the strain usually contains milk proteins such as skim milk, whey, and casein, sugars, yeast extract, and the like, and as a culture method, various general aerobic or anaerobic methods can be appropriately used.
  • the culture or its supernatant may be concentrated, dried, diluted, and the like.
  • the supernatant and the cells of the culture may be separated and the cells may be recovered in a concentrated state.
  • the cells may be subjected to ultrasonic treatment or enzyme treatment to extract the components in the cells, or the culture or the supernatant thereof, the cells or the extract thereof may be dried. These can be used as an active ingredient of the composition of the present invention.
  • the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
  • the pharmaceutical composition of the present invention may be administered orally or parenterally, and is preferably applied by oral administration.
  • the pharmaceutical composition of the present invention may be formulated in the following various oral or parenteral dosage forms, but is not limited thereto.
  • Formulations for oral administration include, for example, tablets, pills, hard/soft capsules, solutions, suspensions, emulsions, and syrups. There are granules, elixirs, etc., and in these formulations, in addition to the active ingredients, one or more diluents or excipients such as commonly used fillers, extenders, wetting agents, disintegrants, lubricants, binders, and surfactants may be used.
  • agar, starch, alginic acid or sodium salt thereof, calcium monohydrogen phosphate anhydride, etc. may be used, and as the lubricant, silica, talc, stearic acid or magnesium salt or calcium salt thereof, polyethylene glycol, etc.
  • magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidine, low-substituted hydroxypropyl cellulose, and the like may be used.
  • lactose dextrose, sucrose, mannitol, sorbitol, cellulose.
  • Glycine and the like may be used as a diluent, and in some cases, a commonly known boiling mixture, absorbent, colorant, flavoring agent, sweetening agent, etc. may be used together.
  • the pharmaceutical composition of the present invention may be sterilized or may contain adjuvants such as preservatives, stabilizers, wetting agents or emulsification accelerators, salts for osmotic pressure control, buffers, and other therapeutically useful substances, and mixing in a conventional manner; It can be formulated according to a granulation or coating method.
  • adjuvants such as preservatives, stabilizers, wetting agents or emulsification accelerators, salts for osmotic pressure control, buffers, and other therapeutically useful substances, and mixing in a conventional manner; It can be formulated according to a granulation or coating method.
  • a suitable dosage of the pharmaceutical composition of the present invention is variously prescribed depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity of the patient. can be
  • the pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container.
  • the formulation may be in the form of a solution, suspension, syrup, or emulsion in oil or aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.
  • the composition of the present invention when prepared as a food composition, it may include, as an active ingredient, a component commonly added during food production, as well as the lactic acid bacteria.
  • the additive includes, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents.
  • the carbohydrate include monosaccharides (eg glucose, fructose, etc.), disaccharides (eg maltose, sucrose, oligosaccharides, etc.) and polysaccharides (eg dextrin, cyclodextrin, etc.). sugar and sugar alcohols such as xylitol, sorbitol, erythritol, etc.
  • flavoring agents natural flavoring agents (taumatin, stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartic acid) tom, etc.) can be used.
  • natural flavoring agents taumatin, stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.)
  • synthetic flavoring agents sacharin, aspartic acid tom, etc.
  • citric acid high fructose
  • sugar glucose
  • acetic acid malic acid
  • fruit juice jujube extract or licorice extract
  • licorice extract may be additionally included in addition to the strain as the active ingredient of the present invention. have.
  • the food composition of the present invention includes processed forms of all natural materials such as food, functional food, nutritional supplement, health food, and food additives.
  • Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
  • the lactic acid bacteria itself may be prepared and consumed in the form of tea, juice, and drink, or may be ingested by granulation, encapsulation and powdering.
  • food includes beverages (including alcoholic beverages), fruits and their processed foods (eg canned fruit, canned food, jam, marmalade, etc.), fish, meat and their processed foods (eg ham, sausage corned beef, etc.) ), breads and noodles (eg udon noodles, soba noodles, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, syrup, dairy products (eg yogurt, fermented milk, butter, cheese, etc.), edible vegetable oils and fats, margarine, It can be prepared by adding the lactic acid bacteria of the present invention, such as vegetable protein, retort food, frozen food, various seasonings (eg, soybean paste, soy sauce, sauce, etc.).
  • the lactic acid bacteria of the present invention in the form of a food
  • the present invention is a Lactobacillus rhamnosus LDTM7511 strain of the present invention described above, a culture of the strain, a concentrate of the culture, a dried product of the culture, and a combination thereof. It provides a method for preventing or treating inflammatory bowel disease, comprising administering to a subject a pharmaceutical composition for preventing or treating inflammatory bowel disease comprising at least one selected from the group consisting of.
  • administer refers to directly administering a therapeutically or prophylactically effective amount of a composition of the present invention to a subject (individual) suffering from, or likely to suffer from, the subject disease. It means that the same amount is formed in the body of
  • the "therapeutically effective amount” of the composition means an amount of the composition sufficient to provide a therapeutic or prophylactic effect to a subject to which the composition is administered, and includes a “prophylactically effective amount”.
  • the term "subject (subject)” is a mammal, including humans, mice, rats, guinea pigs, dogs, cats, horses, cattle, pigs, monkeys, chimpanzees, baboons and rhesus monkeys. . Most specifically, the subject of the present invention is a human.
  • the method for preventing or treating inflammatory bowel disease of the present invention is a method comprising administering the pharmaceutical composition of an aspect of the present invention, the description thereof is omitted in order to avoid excessive duplication of the present specification for overlapping contents. omit
  • the present invention relates to a novel Lactobacillus rhamnosus LDTM7511 strain (Accession No. KCTC 18735P) and a composition for preventing, improving or treating inflammatory bowel disease comprising the same as an active ingredient, Lactobacillus rhamnosus of the present invention
  • the LDTM7511 strain has resistance to the intestinal stress environment as a probiotic, and has been experimentally confirmed to have antibacterial and anti-inflammatory activity, so it can be usefully used for prevention, improvement or treatment of inflammatory bowel disease.
  • 3 is a result of confirming the expression of a protein, which is presented as an inflammatory index, in order to confirm the effect of inhibiting excessive inflammatory response of lactic acid bacteria according to an embodiment of the present invention.
  • 4A to 4C are results of confirming inflammatory cytokine gene expression in order to confirm the effect of suppressing excessive inflammatory response of lactic acid bacteria according to an embodiment of the present invention.
  • 6A to 6D are results of confirming changes in the intestinal microflora through alpha-diversity in order to confirm the effect of improving the intestinal microbiota of lactic acid bacteria according to an embodiment of the present invention.
  • 7A and 7B are results of confirming changes in the intestinal microflora through beta-diversity in order to confirm the effect of improving the intestinal microbiota of lactic acid bacteria according to an embodiment of the present invention.
  • 8A and 8B are results of confirming changes in intestinal microbes through taxonomic classification in order to confirm the effect of improving intestinal microbes of lactic acid bacteria according to an embodiment of the present invention.
  • 9a to 9e are results of confirming changes in intestinal microbes through differential abundance in order to confirm the effect of improving intestinal microbes of lactic acid bacteria according to an embodiment of the present invention.
  • Example 1 Lactobacillus rhamnosus ( Lactobacillus rhamnosus ) Isolation and identification of LDTM7511
  • samples are collected from infant feces, suspended in 0.85% (w/v) NaCl solution, and diluted with 0.2% sodium azide after decimal dilution.
  • MRS de Man Rogosa, and Sharpe, BD difco, USA
  • the smeared strains were anaerobically cultured at 37° C. for 48 hours with an atmospheric composition of 5% CO 2 , 10% H 2 , and 85% N 2 , followed by pure separation.
  • the final isolated strain was identified by amplifying the 16S rRNA gene region and analyzing the nucleotide sequence.
  • Lactobacillus rhamnosus LDTM7511 strain of the present invention isolated in Example 1-1 sugar metabolism characteristics were confirmed using API CHL50 kit (BioM ⁇ rieux, Marcy l'Etoile, France).
  • the Lactobacillus rhamnosus LDTM7511 strain of the present invention is D-arabinose, ribose, galactose, D-glucose, D-fructose, D-mannose, dulcitol, mannitol, sorbitol, N -
  • sugars of acetyl glucosamine, amygdalin, arbutin, esculin, salicin, cellobiose, trehalose, melezitose, ⁇ -gentiobiose, D-tagatose, L-fucose and gluconate could know.
  • the enzyme activity was confirmed using the API ZYM kit (BioMerieux) for the Lactobacillus rhamnosus LDTM7511 strain of the present invention isolated in Example 1-1.
  • the strains cultured at 37 ° C. for 18 hours were centrifuged (15,000 rpm, 8 min, 4 ° C) to recover the cells, washed twice with 1 ⁇ PBS, and absorbance (600 nm) using 0.85% NaCl solution. diluted to 1.0. After inoculating the bacterial solution into each cupule of the API ZYM strip, aerobic culture was performed at 37°C. After 4 hours, ZYM A and B reagents were dropped one drop at a time in each cupule, and scores were recorded from 0 to 5 depending on the intensity of the color that appeared after 5 minutes, and the results are shown in Table 2 below.
  • temperament reaction temperament reaction Blank 0 Naphthol-AS-BI-Phosphohydrolase One alkaline phosphatase One ⁇ -galactosidase 0 Asterace (C4) 2 ⁇ -galactosidase 5 esterase lipase (C8) 0 ⁇ -glucuronidase 0 leucine arylamidase 5 ⁇ -glucosidase 0 valine arylamidase 5 ⁇ -glucosidase 2
  • Example 2 Lactobacillus paracasei ( Lactobacillus paracasei ) Isolation and identification of LDTM7411
  • the microorganism was isolated in the same manner as in Example 1-1, and the finally isolated strain was identified by amplifying the 16S rRNA gene region and analyzing the nucleotide sequence.
  • the Lactobacillus paracasei LDTM7411 strain of the present invention contains D-ribose, galactose, D-glucose, D-fructose, D-mannose, mannitol, sorbitol, ⁇ -methyl-D-glucoside,
  • Using the sugars of N-acetyl glucosamine, amygdalin, arbutin, esculin, salicin, maltose, lactose, saccharose, trehalose, inulin, melezitose, D-turanose, D-tagatose and gluconate could know that
  • temperament reaction temperament reaction Blank 0 Naphthol-AS-BI-Phosphohydrolase One alkaline phosphatase One ⁇ -galactosidase 0 Asterace (C4) One ⁇ -galactosidase One esterase lipase (C8) 0 ⁇ -glucuronidase 0 leucine arylamidase 5 ⁇ -glucosidase 3 valine arylamidase 4 ⁇ -glucosidase 0 Christine arylamidase One N-acetyl- ⁇ -glucosaminidase 0 trypsin 0 ⁇ -mannosidase 0 ⁇ -chymotrypsin 0 ⁇ -fucosidase 0 acid phosphatase One
  • Example 3 Lactobacillus Sake ( Lactobacillus sakei ) Isolation and identification of LDTM7601
  • Microorganisms were isolated in the same manner as in Example 1-1, except that the sample was collected from salted squid purchased at a traditional Korean market instead of infant feces, and the final isolated strain was amplified by 16S rRNA gene region and sequenced were analyzed and identified.
  • the Lactobacillus Sakei LDTM7601 strain of the present invention is L-arabinose, ribose, galactose, D-glucose, D-fructose, D-mannose, N-acetyl glucosamine, esculin, It was found that the sugars of cellobiose, maltose, lactose, melibiose, saccharose, trehalose and gluconate were used.
  • temperament reaction temperament reaction Blank 0 Naphthol-AS-BI-Phosphohydrolase 2 alkaline phosphatase 0 ⁇ -galactosidase One Asterace (C4) 0 ⁇ -galactosidase 0 esterase lipase (C8) 0 ⁇ -glucuronidase 0 leucine arylamidase 5 ⁇ -glucosidase 0 valine arylamidase 4 ⁇ -glucosidase 0 Christine arylamidase 0 N-acetyl- ⁇ -glucosaminidase 0 trypsin 0 ⁇ -mannosidase 0 ⁇ -chymotrypsin 0 ⁇ -fucosidase 0 acid phosphatase 2
  • lactic acid bacteria of the present invention Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601
  • hemolytic activity ⁇ -hemolysis
  • Staphylococcus aureus ATCC25923 American Type Culture Collection, USA
  • a blood solid medium (MB-B1005-P50, Kisan Bio Co., Ltd.) added with 5% (v/v) of defibrinated sheep blood was used, and each bacteria was smeared at 37°C. After anaerobic incubation for 48 hours, the presence or absence of a clear zone was checked. The results are shown in Table 7 below.
  • Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains of the present invention have no hemolytic activity.
  • histidine monohydrochloride a precursor of biogenic amine, in a decarboxylase medium (pH 5.3) (Sigma-aldrich, USA) containing bromocresol purple, tyrosine free base (tyrosine) free base), ornithine monohydrochloride and lysine monohydrochloride (each, Sigma-aldrich, USA) were added to prepare a solid medium, and each of the selected strains was plated at 37° C. After anaerobic culture for 4 days, it was confirmed whether the medium was discolored purple by the alkaline component. The results are shown in Table 8 below.
  • strain decarboxylase (+; positive, -; negative) E. faecalis ATCC29212 + L. paracasei LDTM7411 - L. rhamnosus LDTM7511 - L. sakei LDTM7601 -
  • the Enterococcus faecalis ATCC29212 strain which is a positive control, was discolored purple by an alkaline component, but the lactic acid bacteria of the present invention Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sake LDTM7601 strains were not discolored at all.
  • Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains of the present invention do not produce biogenic amines.
  • Penicillin 32 - 0.002 penicillin Ampicillin (AMP) 256 - 0.015 penicillin Gentamicin (GEN) 256 - 0.015 Aminoglycosides Tetracycline (TET) 256 - 0.015 Tetracycline Erythromycin (ERY) 256 - 0.015 Macrolides Clindamycin (CLI) 256 - 0.015 Lincosamides Vancomycin (VAN) 256 - 0.015 Glycopeptides
  • a total of 7 antibiotics were used at the concentrations shown in Table 9 above, and the minimum inhibitory concentrations (Minimum inhibitory concentrations, MICs) of the lactic acid bacteria of the present invention (Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601) ) LAB susceptibility medium (LSM, Appl. Environ. Microbiol., 2005, Vol.71(12).pp.8982-8986) was used as a medium for confirmation. Antibiotic resistance was confirmed by smearing each lactic acid bacteria on the LSM medium and then culturing for 24 hours at 37°C under aerobic conditions by placing an antibiotic strip. The results are shown in Table 10 below.
  • Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains of the present invention are EFSA, EUCAST, below the antibiotic resistance standards of French breakpoints for 7 types of antibiotics. showed resistance.
  • Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains of the present invention are safe strains without concerns about antibiotic resistance.
  • the Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains of the present invention show superior digestive juice resistance by about 3 to 18% or more than the commercial strain LGG (55.9%).
  • Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 In order to evaluate the intestinal compatibility of the lactic acid bacteria (Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601) of the present invention, colorectal adenocarcinoma-derived HT-29 cell line isolated from Caucasian adult colon (Korean Collection) for Type Cultures, KCTC, Korea) to measure intestinal adhesion. At this time, as a control, Lactobacillus rhamnosus GG (LGG) was used.
  • LGG Lactobacillus rhamnosus GG
  • HT-29 cells were seeded in a 12-well plate and cultured at 37° C. 5% CO 2 conditions for about 4-7 days until they became a monolayer.
  • HT-29 cells were based on Roswell Park Memorial Institute 1640 (RPMI 1640) medium (Gibco, Carlsbad, CA, USA), with 10% heat-inactivated FBS, penicillin, streptomycin, and Fungizone® (amphoteric Sin B, amphotericin B) was added and used.
  • RPMI 1640 Roswell Park Memorial Institute 1640
  • Each lactic acid strain culture medium was centrifuged (15,000rpm, 10min, 4°C) to recover the cells, washed with 1 ⁇ PBS, and diluted so that the absorbance (600nm) was 1.0 in a cell medium not added with antibiotics.
  • 1 ml of the lactic acid bacteria sample was inoculated into each well in which each cell was grown confluently, and cultured at 37° C., 5% CO 2 conditions for 90 minutes.
  • Each well was washed twice with 1 ⁇ PBS and treated with 1 ml of 0.005% Trypsin-EDTA (Gibco, USA) to detach cells. After decimal dilution, the number of viable cells was counted in MRS solid medium (BD difco) by drop plate (DP) method. The results are shown in Table 13 below.
  • Lactobacillus rhamnosus LDTM7511 and Lactobacillus paracasei LDTM7411 strains of the present invention showed similar or superior intestinal adhesion compared to the commercial strain LGG (93.82 ⁇ 0.13%).
  • the Lactobacillus Sakei LDTM7601 strain showed the best intestinal adhesion.
  • the pathogenic inhibitory ability of the lactic acid bacteria of the present invention (Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601), Agar-well diffusion assay (Int. J. Infect. Dis. , 2004, Vol. (8), pp. 39-45).
  • the pathogenic bacteria are general food poisoning bacteria E. coli K88 (E. c), S. aureus ATCC 25923 (S. a), P. aeruginosa PAO1 (P. a), E. faecalis ATCC 29212 (E. f), L. innocua ATCC 33090T (L. i) was used.
  • TSA Teryptic Soy Agar, BD difco, USA
  • LB agar Teryptic Soy Agar, BD difco, USA
  • LB agar Luria-Bertani agar, BD difco, USA
  • H. p Helicobacter pylori ATCC 43504 T
  • C. c Crohn's disease
  • ulcerative colitis atypical colitis Campylobacter coli ATCC 33559 T
  • MAP MAP
  • E. c ulcerative colitis Escherichia coli K88
  • the culture medium was quantitatively dissolved Middlebrook 7H9 Broth Base (Sigma-Aldrich), then glycerol was added, sterilized at 121°C for 10 minutes, and then the medium was cooled to about 45°C.
  • Middlebrook ADC growth supplement was added and dispensed in a sample tube and used after hardening for 2 hours in dark conditions. The indicator bacteria were spread on the medium and cultured for about 4-6 weeks under aerobic conditions at 37°C.
  • the culture medium was prepared and used with the composition shown in Table 16 below. After spreading the indicator bacteria on the medium and putting it in an anaerobic jar, a microaerobic atmosphere was created using the BD GasPak TM EZ Anaerobe Gas Generating Pouch System and cultured at 37° C. for 72 hours.
  • the culture medium was prepared according to the composition of Table 16 and used. After spreading the indicator bacteria on the medium and putting it in an anaerobic jar, a microaerobic atmosphere was created using the BD GasPak TM EZ Anaerobe Gas Generating Pouch System and cultured at 37°C for 72 hours. Finally, E. coli In the case of K88, it was inoculated in a general LB medium and cultured overnight at 37°C for use.
  • the supernatant of each lactic acid bacteria was collected and filtered, mixed with the diluent of the indicator bacteria at a ratio of 1:1, and then the ATP reagent in the BacTiter-Glo assay kit (Promega, Madison, WI) was added and incubated for 5 minutes, followed by a luminometer (Luminometer). ) was used to measure luminescence (RLU).
  • MAP was additionally subjected to a lysis operation due to its thick cell wall (Complex Detection Methods. Iwa Publishing, London, UK, 2009, J. Environ. Sci. Health B, 2012 Vol. (47): 736-741).
  • the doubling time of MAP is generally about 1 hour, it was co-cultured with the supernatant of the lactic acid strain for 6 hours.
  • PBS was used as a blank material, and the groups to which MRS medium was added were set as negative controls (NC). Criteria for the decrease in ATP activity was determined by checking whether lower ATP than the group treated only with sterilized MRS medium as a negative control. Antibacterial activity was confirmed by calculating the following formula. The results are shown in Table 17 below.
  • Lactobacillus rhamnosus LDTM7511 Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601
  • a quantitative assay for NO production was performed.
  • Lactobacillus rhamnosus GG Lactobacillus rhamnosus GG (LGG) was used as a control.
  • NO quantification was measured by repeating the amount of NO 2 3 times using a grease reaction reagent (Promega, USA).
  • RAW264.7 cells (Korea Research Institute of Bioscience and Biotechnology, Bioresource Center) were refrigerated at 4°C until processing.
  • a cell medium supplemented with LPS Lipopolysaccharides from E. coli O111:B4, Sigma-Aldrich
  • LPS Lipopolysaccharides from E. coli O111:B4, Sigma-Aldrich
  • a positive control group was inoculated with 1X PBS instead of lactic acid bacteria, and a medium not treated with LPS was added to the negative control group.
  • the supernatant was collected and NO production was measured using a grease reagent according to the instructions.
  • the amount of NO production was quantified using a nitrite standard curve, and the final result value was expressed as a fold change in the degree of inhibition of NO production compared to the positive control.
  • Table 18 The results are shown in Table 18 below.
  • strain fold change 1st experiment 2nd experiment positive control 1.00 1.00 negative control 0.00 0.00 L. rhamnosus GG 0.84 0.73 L. rhamnosus LDTM7511 0.46 0.53 L. paracasei LDTM7411 0.40 0.50 L. sakei LDTM7601 0.74 0.54 *Values were analyzed by one-way ANOVA (P ⁇ 0.05)
  • Lactobacillus rhamnosus GG LGG was used as a control.
  • HT-29 cell line (KCTC) was treated with recombinant human TNF- ⁇ (PeproTech, USA), and the lactic acid bacteria suspended in the cell culture medium were inoculated.
  • the amount of IL-8 in the sample was measured using the Human IL-8 ELISA MAXTM Deluxe kit (Biolegend, San Diego, USA).
  • the concentration of IL-8 (pg/ml) was calculated by substituting the absorbance into the standard concentration curve derived from the measured values of the human IL-8 standard solution. The results are shown in Table 19 below.
  • strain IL-8 production (pg/ml) 1st experiment 2nd experiment positive control 748.1 1018.4 L. rhamnosus GG 425.5 357.8 L. rhamnosus LDTM7511 384.2 336.9 L. paracasei LDTM7411 346.8 316.1 L. sakei LDTM7601 558.1 666.8 *Values were analyzed by one-way ANOVA (P ⁇ 0.05)
  • Lactobacillus rhamnosus LDTM7511 strain and the Lactobacillus paracasei LDTM7411 strain showed low IL-8 production (IL-8 secretion inhibition ability) compared to the commercial strain Lactobacillus rhamnosus GG (LGG).
  • LGG Lactobacillus rhamnosus GG
  • the Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains of the present invention are all excellent in safety (hemolytic activity/biological amine generation/antibiotic resistance check) Confirmed.
  • Lactobacillus rhamnosus LDTM7511 and Lactobacillus paracasei LDTM7411 strains had very excellent antibacterial activity (inhibiting pathogenic bacteria).
  • a complex strain composition combining the three types of lactic acid bacteria (Lactobacillus rhamnosus LDTM7511, Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601) was further established, and each Follow-up evaluation of lactic acid bacteria was carried out.
  • the administration period of lactic acid bacteria is 4 weeks in total, 2 weeks before DSS (Dextran sulfate sodium) treatment, which is used as an inflammation-inducing substance (lactic acid bacteria settlement period), 1 week DSS treatment (inflammation induction period), and 1 week recovery period (see Table 20 below).
  • DSS Disulfate sodium
  • lactic acid bacteria settlement period 2 weeks before DSS (Dextran sulfate sodium) treatment
  • 1 week DSS treatment inflammation induction period
  • 1 week recovery period see Table 20 below.
  • Lactobacillus rhamnosus GG LGG
  • VSL#3 a complex lactic acid bacteria product
  • NC negative control
  • PC PBS + excipient DW DW DW DSS control
  • PC PBS + excipient DW DSS 1.5% DW L. rhamnosus LDTM7511 (LR) L. rhamnosus LDTM7511 DW DSS 1.5% DW L. paracasei LDTM7411 (LPA) L. paracasei LDTM7411 DW DSS 1.5% DW L. sakei LDTM7601 (LS) L.
  • Example 8 Lactic acid bacteria functional evaluation-2 (mucosal barrier function protective effect: histological damage evaluation)
  • mice organs were removed, and the histological morphology of the mouse colon was observed using the H&E staining technique.
  • Example 9 Functional evaluation of lactic acid bacteria mixture solution-2 (excessive inflammatory reaction inhibitory effect)
  • the weight change of the mouse was measured within about 5% of the initial comparison (see Table 21 below), which means that it does not cause a significant change in body weight when administered for 8 days at a DSS concentration of 1.5%.
  • mice were removed, and the length of the intestine (from the cecum to the large intestine) and the weight of the spleen, known as representative lesions caused by DSS, were measured.
  • the lactic acid bacteria of the present invention did not show a significant difference with the intestinal length of the negative control (NC) ( FIG. 2a ).
  • the weight of the spleen also did not show a significant difference from the negative control of all of the lactic acid bacteria (LR, LPA, LS and MIX) of the present invention (Fig. 2b).
  • the lactic acid bacteria of the present invention relieve the symptoms of DSS-induced intestinal inflammation, thereby inducing the recovery of a short bowel length, a representative symptom of DSS-induced intestinal inflammation, and reducing the size of the enlarged spleen due to inflammation. did.
  • lipocalin-2 (Lcn-2), which is presented as a representative inflammatory index of DSS mouse colitis, in fecal samples after the inflammation induction period and recovery period, was quantified by ELISA technique.
  • Lactobacillus paracasei LDTM7411 and Lactobacillus Sakei LDTM7601 strains (LPA and LS) of the present invention also showed somewhat high values after the inflammation induction period, but showed a 30-50% lower value after the recovery period. could know.
  • the Lactobacillus rhamnosus LDTM7511 strain (LR) of the present invention was found to down-regulate the expression of all inflammatory cytokines the most.
  • Lactobacillus rhamnosus LDTM7511 strain (LR) of the present invention reduces inflammatory cytokines expressed in colon tissues due to intestinal inflammation.
  • Example 10 Functional evaluation of lactic acid bacteria mixture solution-2 (intestinal microorganism improvement effect)
  • the method for measuring ⁇ -glucuronidase is as follows: p-nitrophenyl- ⁇ -D-glucuronide, phosphate buffer, and cecal supernatant After the reaction solution was incubated at 37° C. for 30 minutes, sodium hydroxide was added to terminate the reaction, and only the supernatant was collected through centrifugation and absorbance was measured at a wavelength of 405 nm.
  • the method for measuring tryptophanase is as follows: pyrophosphate, disodium EDTA dehydrate, bovine serum albumin, potassium phosphate buffer, etc.
  • the reaction solution containing the buffer solution, tryptophan, and cecal supernatant was incubated at 37°C for 1 hour. After 1 hour, the reaction was terminated by adding a coloring reagent, and only the supernatant was collected through centrifugation and absorbance was measured at a wavelength of 550 nm.
  • lactic acid bacteria of the present invention can reduce the activity of harmful enzymes in the intestine, thereby lowering the risk of intestinal inflammation induced through DSS and colorectal cancer resulting therefrom.
  • DNA was extracted from the mouse cecum, and the 16s V3-V4 region was amplified by PCR to construct an index library, Sequencing was performed on the Illumina Miseq platform. Then, the sequence was demultiplexed using QIIME2, quality control (DADA2), and taxonomy assignment were performed, and the generated data was analyzed in R with packages such as Phyloseq, DESeq2, and ggplot2. . R and GraphPad were used for visualization, and significance test was calculated by ANOVA of GraphPad.
  • Figs. 6a and 6b Observed (Fig. 6a) and Chaol (Fig. 6b), which are indicators indicating the richness of species, showed the same tendency, lactic acid bacteria of the present invention (LR, LPA, LS and MIX) All of them showed a tendency to increase in species abundance as a whole. In particular, in the case of the complex strain (MIX) of the present invention, it was found that the species abundance increased the most.
  • MIX complex strain
  • FIGS. 6c and 6d which is an indicator of diversity, shows that all of the lactic acid bacteria (LR, LPA, LS and MIX) of the present invention have a tendency to significantly increase species diversity.
  • InvSimpson Fig. 6d
  • Fig. 6d also had a similar tendency to Shannon, and in particular, it was found that the Lactobacillus rhamnosus LDTM7511 strain (LR) and the composite strain (MIX) of the present invention had the highest species diversity.
  • Intergroup distance Generalized UniFrac was used to measure similarity (based on assigned microbial communities and phylogeny) between different groups. The ordination was presented as NMDS (Non-metric Multidimensional Scaling).
  • taxonomy classification of each group was converted to relative abundance and expressed at the Phylum and Family level.
  • Lactobacillus rhamnosus LDTM7511 strain (LR) of the present invention clearly regulates the intestinal microbial community changed to the DSS control (PC), in particular, the genera Allobaculum and Bifidobacterium , despite the same L. rhamnosus. It was also confirmed that this was controlled in a manner different from that of LGG.
  • the concentration of short-chain fatty acid (butyrate) was measured using gas chromatography/mass spectrometer in the feces collected just before mouse euthanasia.
  • the analysis method is as follows: The fecal sample was prepared by crushing, and after derivatization, the concentration of short-chain fatty acids in the feces was quantified through gas chromatography/mass spectrometry equipment. On the other hand, the state of high concentration of short-chain fatty acids is known as an indicator of metabolic dysregulation, and is particularly related to intestinal permeability and intestinal dysbiosis.
  • lactic acid bacteria As can be seen in Figure 10, all of the lactic acid bacteria (LR, LPA, LS and MIX) of the present invention showed a tendency to decrease the concentration of short-chain fatty acids compared to the DSS control (PC), in particular, the Lactobacillus rhamnosus LDTM7511 strain (LR) of the present invention.
  • the concentration of short-chain fatty acids was measured as the lowest concentration.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une nouvelle Lactobacillus rhamnosus LDTM7511 (N° de dépôt : KCTC 18735P) et une composition pour la prévention, l'amélioration ou le traitement des maladies inflammatoires de l'intestin, la composition comprenant cette souche comme ingrédient actif. KCTC 18735P) et une composition pour la prévention, l'amélioration ou le traitement des maladies intestinales inflammatoires, la composition comprenant cette souche comme ingrédient actif. Il a été confirmé expérimentalement que la souche Lactobacillus rhamnosus LDTM7511 de la présente invention a une résistance à un environnement de stress intestinal en tant que probiotique, et a des activités antibactériennes et anti-inflammatoires, et peut donc être utilisée efficacement pour prévenir, améliorer ou traiter les maladies intestinales inflammatoires.
PCT/KR2021/002857 2020-03-10 2021-03-09 Souche de lactobacillus rhamnosus ayant une fonction immunomodulatrice intestinale et une activité préventive ou thérapeutique pour les maladies intestinales inflammatoires WO2021182829A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200029448A KR102166461B1 (ko) 2020-03-10 2020-03-10 장관 면역조절 기능과 염증성 장 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 균주
KR10-2020-0029448 2020-03-10

Publications (1)

Publication Number Publication Date
WO2021182829A1 true WO2021182829A1 (fr) 2021-09-16

Family

ID=72882998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/002857 WO2021182829A1 (fr) 2020-03-10 2021-03-09 Souche de lactobacillus rhamnosus ayant une fonction immunomodulatrice intestinale et une activité préventive ou thérapeutique pour les maladies intestinales inflammatoires

Country Status (2)

Country Link
KR (1) KR102166461B1 (fr)
WO (1) WO2021182829A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958658A (zh) * 2022-05-11 2022-08-30 广西爱生生命科技有限公司 一株鼠李糖乳杆菌a21149及其应用
CN115029270A (zh) * 2022-06-21 2022-09-09 江南大学 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102166461B1 (ko) * 2020-03-10 2020-10-15 주식회사 종근당바이오 장관 면역조절 기능과 염증성 장 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 균주
KR102297271B1 (ko) 2020-11-30 2021-09-03 주식회사 종근당바이오 당뇨 및 고지혈증을 포함하는 대사성 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 nbm 17-4 균주
KR102536371B1 (ko) * 2020-12-10 2023-05-23 노재국 락토바실러스 람노서스 균주, 그 배양액, 또는 그 추출물을 유효성분으로 포함하는 항염증, 피부 보습, 피부 장벽 강화, 및 피부 재생 촉진용 조성물
CN112481175B (zh) * 2020-12-29 2022-08-02 江南大学 一株能预防和缓解溃疡性结肠炎的鼠李糖乳杆菌及其应用
CN113040219A (zh) * 2021-03-26 2021-06-29 内蒙古民族大学 一种绿豆芽酸奶的制备方法
KR20230146369A (ko) * 2022-04-12 2023-10-19 서울대학교산학협력단 신규한 미생물 및 이를 포함하는 조성물
KR102578409B1 (ko) * 2023-03-17 2023-09-15 주식회사 락토메이슨 락티카제이바실러스 람노수스 lm1019 및 스타터 균주를 포함하는 면역 증진용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1982437A (zh) * 2005-12-16 2007-06-20 统一企业(中国)投资有限公司 一种新颖的耐酸耐胆盐、抗肠道致病菌和抗氧化能力鼠李糖乳杆菌株
EP2256498A1 (fr) * 1999-08-11 2010-12-01 Cedars Sinai Medical Center Procédés de diagnostic ou de traitement de syndrome d'intestin douloureux et autres troubles
KR20110019355A (ko) * 2008-03-19 2011-02-25 꽁빠니 자베 다노느 락토바실러스 람노서스 균주
CN106754470A (zh) * 2016-11-11 2017-05-31 中国农业科学院饲料研究所 一株人母乳来源的鼠李糖乳杆菌及其应用
KR20190111582A (ko) * 2018-03-23 2019-10-02 (주)바이오일레븐 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 파라카제이 균주
KR102166461B1 (ko) * 2020-03-10 2020-10-15 주식회사 종근당바이오 장관 면역조절 기능과 염증성 장 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 균주

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100982437B1 (ko) * 2010-02-10 2010-09-15 김영춘 걸레받이
KR101870960B1 (ko) 2016-07-15 2018-06-25 한국식품연구원 락토바실러스 사케이 k040706을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256498A1 (fr) * 1999-08-11 2010-12-01 Cedars Sinai Medical Center Procédés de diagnostic ou de traitement de syndrome d'intestin douloureux et autres troubles
CN1982437A (zh) * 2005-12-16 2007-06-20 统一企业(中国)投资有限公司 一种新颖的耐酸耐胆盐、抗肠道致病菌和抗氧化能力鼠李糖乳杆菌株
KR20110019355A (ko) * 2008-03-19 2011-02-25 꽁빠니 자베 다노느 락토바실러스 람노서스 균주
CN106754470A (zh) * 2016-11-11 2017-05-31 中国农业科学院饲料研究所 一株人母乳来源的鼠李糖乳杆菌及其应用
KR20190111582A (ko) * 2018-03-23 2019-10-02 (주)바이오일레븐 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 파라카제이 균주
KR102166461B1 (ko) * 2020-03-10 2020-10-15 주식회사 종근당바이오 장관 면역조절 기능과 염증성 장 질환의 예방 또는 치료 활성을 갖는 락토바실러스 람노서스 균주

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114958658A (zh) * 2022-05-11 2022-08-30 广西爱生生命科技有限公司 一株鼠李糖乳杆菌a21149及其应用
CN114958658B (zh) * 2022-05-11 2023-08-11 广西爱生生命科技有限公司 一株抑制幽门螺旋杆菌的鼠李糖乳杆菌a21149及其应用
CN115029270A (zh) * 2022-06-21 2022-09-09 江南大学 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用
CN115029270B (zh) * 2022-06-21 2023-11-28 江南大学 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用

Also Published As

Publication number Publication date
KR102166461B1 (ko) 2020-10-15

Similar Documents

Publication Publication Date Title
WO2021182829A1 (fr) Souche de lactobacillus rhamnosus ayant une fonction immunomodulatrice intestinale et une activité préventive ou thérapeutique pour les maladies intestinales inflammatoires
WO2018143678A1 (fr) Nouvelles bactéries lactiques et leur utilisation
EP3454869A1 (fr) Composition comprenant une bactérie lactique pour la prévention et le traitement de la vaginose et son utilisation
WO2020075949A1 (fr) Nouvelle souche de lactobacillus plantarum atg-k2, atg-k6 ou atg-k8 et composition de prévention ou de traitement de la vaginite comprenant celle-ci
WO2017047968A1 (fr) Nouveau lactobacillus présentant diverses fonctions et son utilisation
WO2021221398A1 (fr) Nouvelles bactéries d'acide lactique ayant un excellent effet d'amélioration de la fonction immunitaire, et composition alimentaire, composition alimentaire fonctionnelle pour la santé et probiotiques les comprenant
WO2016053003A1 (fr) Procédé pour la préparation d'une préparation microbienne dans lequel de l'aglycone s'accumule dans des cellules et préparation microbienne préparée par ce procédé
WO2021162282A1 (fr) Composition utilisant une nouvelle souche de lactobacillus plantarum kc3 pour la prévention ou le traitement d'une déficience immunitaire, d'une maladie inflammatoire respiratoire, d'une allergie et de l'asthme et son utilisation
WO2017204415A1 (fr) Nouvelles bactéries lactiques permettant de réguler la glycémie et leur utilisation
WO2019066599A2 (fr) Nouvelles bactéries d'acide lactique et leur utilisation
WO2018186700A1 (fr) Composition comprenant des ferments lactiques améliorés du point de vue de l'adhérence intestinale par enrobage avec de la fibroïne de soie
WO2013151362A1 (fr) Nouveau bacillus subtilis
WO2017047962A1 (fr) Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive
WO2021141473A1 (fr) Nouvelle souche de lactobacillus plantarum, polysaccharides dérivés de la souche et leur utilisation
WO2021040186A1 (fr) Souche d'akkermansia muciniphila eb-amdk27 et son utilisation
WO2021194225A1 (fr) Souche de lactobacillus delbrueckii subsp. lactis ckdb001 et composition de prévention d'amélioration ou de traitement de stéatose hépatique non alcoolique la comprenant
WO2018004224A2 (fr) Nouveau microorganisme appartenant à la famille des sporichthyaceae et son utilisation
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
WO2018169297A1 (fr) Bactéries lactiques tryptophanase-négatives, compositions et utilisations correspondantes
WO2022030662A1 (fr) Nouvelle souche de bacillus velezensis l2 isolée de la solution de fermentation d'anchois, et aekjeot préparé à partir de celle-ci
WO2019088379A1 (fr) Nouvelles bactéries lactiques et leur utilisation
WO2020262755A1 (fr) Nouvelle composition probiotique pour la régulation de l'immunité intestinale
WO2019103198A1 (fr) Souche de lactobacillus fermentum kbl 375 et son utilisation
WO2021066549A1 (fr) Souche de lactobacillus acidophilus kbl409 et son utilisation
WO2022240224A1 (fr) Composition contenant de la gomme gellane en tant que principe actif pour améliorer le microbiote intestinal et composition la contenant pour le soulagement, la prévention ou le traitement d'une maladie métabolique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21767167

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21767167

Country of ref document: EP

Kind code of ref document: A1